Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease

American Journal of Nephrology

Volumn 33, Issue 3, 2011, Pages 250-259

  Gawdzik, Joseph ^a   Mathew, Liby ^a   Kim, Gene ^a   Puri, Tipu S ^a   Hofmann Bowman, Marion A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Blood urea nitrogen; Chronic kidney disease; Receptor for advanced glycation endproducts

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CALGRANULIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; S100A12 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; GENE EXPRESSION; LIGATION; MOUSE; NONHUMAN; OSTEOBLAST; OXIDATIVE STRESS; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA; CALCINOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; S100 PROTEINS; VASCULAR DISEASES;

EID: 79952105151     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000324693     Document Type: Article

References (36)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Mori Y, Kosaki A, Kishimoto N, Kimura T, Iida K, Fukui M, Nakajima F, Nagahara M, Urakami M, Iwasaka T, Matsubara H: In-creased plasma S100A12 (EN-RAGE) levels in hemodialysis patients with atherosclero-sis. Am J Nephrol 2009; 29:18-24.
3. Nakashima A, Carrero JJ, Qureshi AR, Mi-yamoto T, Anderstam B, Barany P, Heim-burger O, Stenvinkel P, Lindholm B: Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the pro-inflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis pa-tients. Clin J Am Soc Nephrol 2010; 12:2213-2219.
4. Hofmann MA, Drury S, Fu C, Qu W, Tagu-chi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel pro-inflammatory axis: a central cell surface re-ceptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901. (Pubitemid 29375048)
5. Leclerc E, Fritz G, Vetter SW, Heizmann CW: Binding of S100 proteins to RAGE: an up-date. Biochim Biophys Acta 2009; 1793: 993-1007.
6. -/- mice. J Clin Invest 2008; 118: 183-194.
7. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bier-haus A, Cooper ME, Jandeleit-Dahm KA: Receptor for advanced glycation end prod-ucts (RAGE) deficiency attenuates the devel-opment of atherosclerosis in diabetes. Dia-betes 2008; 57: 2461-2469.
8. Reiniger N, Lau K, McCalla D, Eby B, Cheng B, Lu Y, Qu W, Quadri N, Ananthakrishnan R, Furmansky M, Rosario R, Song F, Rai V, Weinberg A, Friedman R, Ramasamy R DAgati V, Schmidt AM: Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 2010; 59: 2043-2054.
9. Sourris KC, Morley AL, Koitka A, Samuel P, Coughlan MT, Penfold SA, Thomas MC, Bierhaus A, Nawroth PP, Yamamoto H, Allen TJ, Walther T, Hussain T, Cooper ME, Forbes JM: Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. Diabetologia 2010; 53: 2442-2451.
10. Burke AP, Kolodgie FD, Zieske A, Fowler DR, Weber DK, Varghese PJ, Farb A, Vir-mani R: Morphologic findings of coronary atherosclerotic plaques in diabetics: a post-mortem study. Arterioscler Thromb Vasc Biol 2004; 24:1266-1271. (Pubitemid 38880019)
11. Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM: S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2010; 106:145-154.
12. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G, Earley J, Mc-Nally EM: S100A12 in vascular smooth mus-cle accelerates vascular calcification in apo-lipoprotein E-null mice by activating an osteogenic gene regulatory program. Arte-rioscler Thromb Vasc Biol 2011; 31:337-344.
13. Foell D, Kane D, Bresnihan B, Vogl T, Nacken W, Sorg C, Fitzgerald O, Roth J: Ex-pression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 1383-1389. (Pubitemid 37407031)
14. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J: Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52:847-853. (Pubitemid 36613492)
15. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A: Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 2006; 91:4628-4634. (Pubitemid 44833448)
16. Foell D, Ichida F, Vogl T, Yu X, Chen R, Mi-yawaki T, Sorg C, Roth J: S100A12 (EN-RAGE) in monitoring Kawasaki disease. Lancet 2003; 361: 1270-1272. (Pubitemid 36428584)
17. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C: Myeloid-related pro-tein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-de-pendent pathway. J Biol Chem 1997; 272: 9496-9502. (Pubitemid 27154966)
18. Fuellen G, Nacken W, Sorg C, Kerkhoff C: Computational searches for missing ortho-logs: the case of S100A12 in mice. OMICS 2004; 8:334-340. (Pubitemid 40250750)
19. Puri TS, Shakaib MI, Chang A, Mathew L, Olayinka O, Minto AW, Sarav M, Hack BK, Quigg RJ: Chronic kidney disease induced in mice by reversible unilateral ureteral ob-struction is dependent on genetic back-ground. Am J Physiol Renal Physiol 2010; 298:F1024-F1032.
20. Ghavami S, Eshragi M, Ande SR, Chazin WJ, Klonisch T, Halayko AJ, McNeill KD, Ha-shemi M, Kerkhoff C, Los M: S100A8/A9 in-duces autophagy and apoptosis via ROS-me-diated cross-talk between mitochondria and lysosomes that involves BNIP3. Cell Res 2010; 20: 314-331.
21. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB: S100B-RAGE-me-diated augmentation of angiotensin II-in-duced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 2003; 52:2381-2388. (Pubitemid 37059510)
22. Hofmann MA, Lalla E, Lu Y, Gleason MR Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM: Hyper-homocysteinemia enhances vascular in-flammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-683. (Pubitemid 32225353)
23. Ke XD, Foucault-Bertaud A, Genovesio C, Dignat-George F, Lamy E, Charpiot P: Ho-mocysteine modulates the proteolytic poten-tial of human arterial smooth muscle cells through a reactive oxygen species dependant mechanism. Mol Cell Biochem 2010; 335: 203-210.
24. Hosaka N, Mizobuchi M, Ogata H, Kumata C, Kondo F, Koiwa F, Kinugasa E, Akizawa T: Elastin degradation accelerates phos-phate-induced mineralization of vascular smooth muscle cells. Calcif Tissue Int 2009; 85:523-529.
25. Byon CH, Javed A, Dai Q, Kappes JC, Clem-ens TL, Darley-Usmar VM, McDonald JM, Chen Y: Oxidative stress induces vascular calcification through modulation of the os-teogenic transcription factor Runx2 by AKT signaling. J Biol Chem 2008; 283: 15319-15327.
26. DAgati V, Schmidt AM: RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010; 6: 352-360.
27. Yan SF, Ramasamy R, Schmidt AM: The RAGE axis: a fundamental mechanism sig-naling danger to the vulnerable vasculature. Circ Res 2010; 106: 842-853.
28. Burton DG, Matsubara H, Ikeda K: Patho-physiology of vascular calcification: Pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010; 45: 819-824.
29. Gottsch JD, Eisinger SW, Liu SH, Scott AL: Calgranulin C has filariacidal and filaria-static activity. Infect Immun 1999; 67:6631-6636.
30. Berthier S, Paclet MH, Lerouge S, Roux F, Vergnaud S, Coleman AW, Morel F: Chang-ing the conformation state of cytochrome b558 initiates NADPH oxidase activation: MRP8/MRP14 regulation. J Biol Chem 2003; 278: 25499-25508. (Pubitemid 36835301)
31. San Martin A, Foncea R, Laurindo FR, Ebensperger R, Griendling KK, Leighton F: Nox1-based NADPH oxidase-derived super-oxide is required for VSMC activation by ad-vanced glycation end-products. Free Radic Biol Med 2007; 42:1671-1679. (Pubitemid 46617146)
32. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y Grant SL, Lambeth JD, Griendling KK: Novel gp91(phox) homo-logues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 2001; 88:888-894. (Pubitemid 32441466)
33. Gianni D, Diaz B, Taulet N, Fowler B, Court-neidge SA, Bokoch GM: Novel p47(phox)-related organizers regulate localized NADPH oxidase 1 (Nox1) activity. Sci Signal 2009; 2:ra54.
34. Hudson BI, Kalea AZ, Del Mar Arriero M, Harja E, Boulanger E, DAgati V, Schmidt AM: Interaction of the RAGE cytoplas-mic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008; 283:34457-34468.
35. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280:E685-E694.
36. Rosenberg S, Elashoff MR, Beineke P, Daniels SE, Wingrove JA, Tingley WG, Sager PT, Sehnert AJ, Yau M, Kraus WE, Newby LK, Schwartz RS, Voros S, Ellis SG, Ta-hirkheli N, Waksman R, McPherson J, Lan-sky A, Winn ME, Schork NJ, Topol EJ: Mul-ticenter validation of the diagnostic accura-cy of a blood-based gene expression test for assessing obstructive coronary artery dis-ease in nondiabetic patients. Ann Intern Med 2010; 153: 425-434.